A Phase 3 interventional study of Valsartan and amlodipine in Hypertension and Chronic Kidney Disease, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-07-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 74th largest by enrollment of the 139 interventional ones that give a count, is one of 7 that started in 2011, is one of 53 in phase 3, and was the 111th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 141st largest by enrollment of the 222 interventional ones that give a count, is one of 6 that started in 2011, is one of 108 in phase 3, and was the 194th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any physical abnormalities or clinically relevant abnormal laboratory values (other than those relating to renal function) obtained at the screening visit. Including the following:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valsartan starting dose: ≥18 kg to \<35 kg is 40 mg, ≥35 kg to \<80 kg is 80 mg, ≥80 kg to ≤160 kg is 160 mg for 1 week then Valsartan maintenance dose: ≥18 kg to \<35 kg is 80 mg, ≥35 kg to \<80 kg is 160 mg, ≥80 kg to ≤160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.
Drug: Valsartan · Drug: amlodipine · Drug: Hydrochlorothiazide
week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
Also known as: VAL489
added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
Also known as: HCTZ
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)
Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit.
Time frame: Baseline, End Point (Week 78 or Last observation carried forward (LOCF)
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)
Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit.
Time frame: Baseline, End Point (Week 78 or Last observation carried forward (LOCF)
Number of Participants With MSSBP, MSDBP and (MSSBP and MSDBP Combined) < 95th Percentile for Gender, Age, and Height
Number of Participants with Mean sitting systolic (MSSBP) and mean sitting diastolic(MSDBP) blood pressure and both combined less than the 95th percentile for age, gender and height
Time frame: End Point (Week 78 or Last observation carried forward (LOCF)
Percentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point
Percentage of Patients with CKD who had Urine albumin creatinine reduction \>/= 50% from baseline
Time frame: Baseline, End Point (Week 78 or Last observation carried forward (LOCF)
Percentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point
Percentage of Patients with CKD who had eGFR decrease \> 25 % from Baseline
Time frame: Baseline, End Point (Week 78 or Last observation carried forward (LOCF)
A 1 arm study of valsartan but with 2 groups for analyses. The valsartan +antihypertensive group includes the patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.
| Milestone | CKD Patients: Valsartan + Antihypertensive Group | CKD Patients: Valsartan Alone | Non-CKD Patients: Valsartan + Antihypertensive Group | Non-CKD Patients: Valsartan Alone |
|---|---|---|---|---|
| Started | 23 | 52 | 18 | 57 |
| Completed | 16 | 37 | 14 | 50 |
| Not completed | 7 | 15 | 4 | 7 |
| Withdrew: Adverse event | 6 | 9 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 3 |
| Withdrew: Abnormal laboratory value(s) | 0 | 1 | 0 | 0 |
| Withdrew: Administrative problems | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 0 | 1 | 0 |
Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sSBP measurements were used as the average sitting office blood pressure for that visit.
| millimeter(s) of mercury (mmHg) | Valsartan + Antihypertensive Group | Valsartan Alone |
|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF) | -13.3 ± 13.69 | -15.5 ± 13.35 |
Number of Participants with Mean sitting systolic (MSSBP) and mean sitting diastolic(MSDBP) blood pressure and both combined less than the 95th percentile for age, gender and height
| Number of Participants | Valsartan + Antihypertensive Group | Valsartan Alone |
|---|---|---|
| MSSBP (n=39, 105) | 23 | 90 |
| MSDBP (n=28, 51) | 20 | 47 |
| MSSBP and MSDBP combined (n=40, 105) | 22 | 88 |
Percentage of Patients with CKD who had Urine albumin creatinine reduction \>/= 50% from baseline
| Percentage of patients | Valsartan + Antihypertensive Group | Valsartan Alone |
|---|---|---|
| Percentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point | 50.0 ± 404.08 | 41.9 ± 138.66 |
Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participants remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 2 to 3 minute intervals and the mean of three sDBP measurements were used as the average sitting office blood pressure for that visit.
| millimeter(s) of mercury (mmHg) | Valsartan + Antihypertensive Group | Valsartan Alone |
|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF) | -10.3 ± 11.94 | -10.8 ± 11.45 |
Percentage of Patients with CKD who had eGFR decrease \> 25 % from Baseline
| Percentage of patients | Valsartan + Antihypertensive Group | Valsartan Alone |
|---|---|---|
| Percentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point | 30.4 ± 404.08 | 27.5 ± 138.66 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan + Antihypertensive Group | — | 8/41 (19.5%) | 34/41 (82.9%) |
| Valsartan Alone | — | 7/109 (6.4%) | 68/109 (62.4%) |
| CKD Patients: Valsartan + Antihypertensive Group | — | 7/23 (30.4%) | 18/23 (78.3%) |
| CKD Patients: Valsartan Alone | — | 4/52 (7.7%) | 36/52 (69.2%) |
| Non-CKD Patients: Valsartan + Antihypertensive Group | — | 1/18 (5.6%) | 16/18 (88.9%) |
| Non-CKD Patients: Valsartan Alone | — | 3/57 (5.3%) | 32/57 (56.1%) |
| Event | Valsartan + Antihypertensive Group | Valsartan Alone | CKD Patients: Valsartan + Antihypertensive Group | CKD Patients: Valsartan Alone | Non-CKD Patients: Valsartan + Antihypertensive Group | Non-CKD Patients: Valsartan Alone |
|---|---|---|---|---|---|---|
| Lupus nephritisRenal and urinary disorders | 3/41 | 1/109 | 3/23 | 1/52 | 0/18 | 0/57 |
| HypertensionVascular disorders | 1/41 | 0/109 | 0/23 | 0/52 | 1/18 | 0/57 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/41 | 0/109 | 1/23 | 0/52 | 0/18 | 0/57 |
| Oesophageal polypGastrointestinal disorders | 1/41 | 0/109 | 1/23 | 0/52 | 0/18 | 0/57 |
| Face oedemaGeneral disorders | 1/41 | 0/109 | 1/23 | 0/52 | 0/18 | 0/57 |
| Oedema peripheralGeneral disorders | 1/41 | 0/109 | 1/23 | 0/52 | 0/18 | 0/57 |
| GastroenteritisInfections and infestations | 1/41 | 0/109 | 1/23 | 0/52 | 0/18 | 0/57 |
| PneumoniaInfections and infestations | 1/41 | 1/109 | 1/23 | 1/52 | 0/18 | 0/57 |
| Glomerular filtration rate decreasedInvestigations | 1/41 | 0/109 | 1/23 | 0/52 | 0/18 | 0/57 |
| SynovitisMusculoskeletal and connective tissue disorders | 1/41 | 0/109 | 1/23 | 0/52 | 0/18 | 0/57 |
| Event | Valsartan + Antihypertensive Group | Valsartan Alone | CKD Patients: Valsartan + Antihypertensive Group | CKD Patients: Valsartan Alone | Non-CKD Patients: Valsartan + Antihypertensive Group | Non-CKD Patients: Valsartan Alone |
|---|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 18/41 | 18/109 | 12/23 | 12/52 | 6/18 | 6/57 |
| PyrexiaGeneral disorders | 12/41 | 18/109 | 8/23 | 12/52 | 4/18 | 6/57 |
| HeadacheNervous system disorders | 14/41 | 23/109 | 8/23 | 11/52 | 6/18 | 12/57 |
| NasopharyngitisInfections and infestations | 11/41 | 22/109 | 7/23 | 14/52 | 4/18 | 8/57 |
| Upper respiratory tract infectionInfections and infestations | 2/41 | 17/109 | 1/23 | 12/52 | 1/18 | 5/57 |
| DizzinessNervous system disorders | 8/41 | 17/109 | 4/23 | 6/52 | 4/18 | 11/57 |
| VomitingGastrointestinal disorders | 5/41 | 4/109 | 4/23 | 3/52 | 1/18 | 1/57 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 4/41 | 3/109 | 3/23 | 2/52 | 1/18 | 1/57 |
| Abdominal painGastrointestinal disorders | 4/41 | 7/109 | 2/23 | 4/52 | 2/18 | 3/57 |
| InfluenzaInfections and infestations | 3/41 | 1/109 | 1/23 | 0/52 | 2/18 | 1/57 |
| Age, Continuous(years) | CKD Patients: Valsartan + Antihypertensive Group | CKD Patients: Valsartan Alone | Non-CKD Patients: Valsartan + Antihypertensive Group | Non-CKD Patients: Valsartan Alone | Total |
|---|---|---|---|---|---|
| Mean | 12.90 ± 3.35 | 12.30 ± 3.20 | 13.79 ± 2.64 | 14.37 ± 2.83 | 13.36 ± 3.130 |
| Age, Customized(participants) | CKD Patients: Valsartan + Antihypertensive Group | CKD Patients: Valsartan Alone | Non-CKD Patients: Valsartan + Antihypertensive Group | Non-CKD Patients: Valsartan Alone | Total |
|---|---|---|---|---|---|
| 6 - 11 years | 10 | 22 | 3 | 10 | 45 |
| 12 - 17 years | 13 | 30 | 15 | 47 | 105 |
| Sex: Female, Male(Participants) | CKD Patients: Valsartan + Antihypertensive Group | CKD Patients: Valsartan Alone | Non-CKD Patients: Valsartan + Antihypertensive Group | Non-CKD Patients: Valsartan Alone | Total |
|---|---|---|---|---|---|
| Female | 12 | 16 | 3 | 20 | 51 |
| Male | 11 | 36 | 15 | 37 | 99 |
The record gives a start of Aug 2011, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valsartan